Reducing Pain from Propofol Injection: A Comparison of Two Lignocaine Treatments in Adults

TO COMPARE 15 ML OF 0.4% LIGNOCAINE VERSUS 3ML OF 2% LIGNOCAINE FOR PREVENTING PAIN ASSOCIATED WITH PROPOFOL INJECTION - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089560

Enrollment

150

Registered

2025-06-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical Health Condition 2: K00-K95- Diseases of the digestive system Health Condition 3: G00-G99- Diseases of the nervous system Health Condition 4: H60-H95- Diseases of the ear and mastoid process Health Condition 5: N00-N99- Diseases of the genitourinary system Health Condition 6: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: 15ml of 0.4% inj Lignocaine given intravenously: The study population is divided into 2 groups of 75 patients each . Group A using 15ml of 0.4% inj lignocaine Control Intervention1: 3ml

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients giving informed written consent for participation in study. 2. Patients posted for surgeries under general anesthesia receiving propofol as an induction agent. 3. Age of the patient between 18-65 of either sex. 4. Patients belonging to ASA class I and II.

Exclusion criteria

Exclusion criteria: 1. Patients with history of any contraindication to propofol or lignocaine. 2. Patients with thrombophlebitis. 3. Patients with history of epilepsy. 4. Patients with psychiatric disorders. 5. Pregnant patients. 6. Patients who had received analgesics prior to anaesthesia.

Design outcomes

Primary

Measure	Time frame
TO COMPARE 15 ML OF 0.4% LIGNOCAINE VERSUS 3ML OF 2% LIGNOCAINE FOR PREVENTING PAIN ASSOCIATED WITH PROPOFOL INJECTIONTimepoint: Immediately after propofol injection (within 10 seconds)	—

Secondary

Measure	Time frame
To compare Numeric Rating Scale score & Withdrawal Response Score using 15 ml of 0.4 % lignocaine (group A) & 3ml of 2% lignocaine (group B) for preventing pain associated with propofol injection Timepoint: Immediately after propofol injection within ten seconds; To observe side effects if any & compare amongst the group A & group B.Timepoint: At baseline immediately post injection 15 minutes post injection & at recovery	—

Measure

Time frame

To compare Numeric Rating Scale score & Withdrawal Response Score using 15 ml of 0.4 % lignocaine (group A) & 3ml of 2% lignocaine (group B) for preventing pain associated with propofol injection Timepoint: Immediately after propofol injection within ten seconds; To observe side effects if any & compare amongst the group A & group B.Timepoint: At baseline immediately post injection 15 minutes post injection & at recovery

—

Countries

India

Contacts

Public ContactDr Ajay Kumar Sinha

Government Medical Haldwani

drajayksinha@yahoo.co.in9897672301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026